Guizhou Bailing Group Pharmaceutical (002424.SZ): Approval received for clinical trials of Tangning Tongluo tablets.
ST Bairun (002424.SZ) announcement, the company's wholly-owned subsidiary Bairun Yuxiu (Zhuhai) Pharmaceutical Co., Ltd. (...
Guizhou Bailing Group Pharmaceutical (002424.SZ) announced that its wholly-owned subsidiary, Bailin Yuxiu (Zhuhai) Pharmaceutical Co., Ltd. ("Bailin Yuxiu"), has received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration (NMPA). The clinical trial application for Tangning Tongluo Tablets submitted by Bailin Yuxiu has been approved, allowing the product to conduct Phase III clinical trials for diabetic retinopathy.
Related Articles
New Stock Outlook | With the support of more than ten state-owned shareholders, can the merger and acquisition growth story of Tiandi HeXing earn market approval?
Guosen: The final mindset of asset trend convergence.
Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.
New Stock Outlook | With the support of more than ten state-owned shareholders, can the merger and acquisition growth story of Tiandi HeXing earn market approval?
Guosen: The final mindset of asset trend convergence.
Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.
RECOMMEND
Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026
Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026
Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026
